[Pharmacogenetics of the local thrombolysis in patients with deep vein thrombosis].
Thrombophilia, the state of increased tendency for blood clotting, is considered the disorder of a complex etiology, caused by both environmental and genetic factors. As gene variants predisposing to thrombophilia and influencing the increased risk of vein thrombosis might influence response to local thrombolysis, the aim of the work was to characterize the pharmacogenetic conditions for local streptokinase treatment in patients with a deep vein thrombosis (DVT) of lower extremities based on the following polymorphism analyses: G1691A polymorphism of factor V (FV), G20210A polymorphism of prothrombin (PT), A4250G (Thr312Ala) polymorphism of fibrinogen-alpha (FGA), G(-455)A polymorphism of fibrinogen-beta (FGB), 4G/5G polymorphism of plasminogen activator inhibitor type 1(PAI-1) and insertion/deletion (I/D) polymorphism of tissue plasminogen activator (t-PA). The study included 40 DVT patients who underwent a local thrombolytic treatment within 14-day period from diagnosis. Full recanalization was achieved in 20 subjects (50%) [group R(+)], whereas incomplete or total lack of recanalization was identified in the remaining 20 patients [group R(-)]. No major complications of thrombolytic treatment occurred in the studied group. In the case of prothrombin gene all individuals carried homozygous wild type genotype (GG). Prevalence of the genotypes and alleles of the remaining five polymorphisms did not differ significantly between the groups R(+) and R(-). Neither sex nor age, smoking or time period from diagnosis to introduction of the thrombolytic treatment significantly influenced treatment efficacy. The results of the study suggest that a local thrombolysis with streptokinase introduced within two week period from the diagnosis is a safe and efficient method of treatment for deep vein thrombosis of lower extremities. However, size of the group is insufficient to clearly determine the association between investigated polymorphisms and efficacy of local treatment with streptokinase.
Falkowski
Aleksander
A
Katedra i Zakład Radiologii Ogólnej i Stomatologicznej Pomorskiej AM w Szczecinie.
Kaczmarczyk
Mariusz
M
Goracy
Iwona
I
Górecka-Szyld
Barbara
B
Poncyljusz
Wojciech
W
Parczewski
Miłosz
M
Ciechanowicz
Andrzej
A
D000328:Adult; D000368:Aged; D001779:Blood Coagulation Factors / Q000235:genetics*; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage*; D006801:Humans; D007866:Leg; D008297:Male; D008875:Middle Aged; D011110:Polymorphism, Genetic; D013300:Streptokinase / Q000008:administration & dosage*; D016896:Treatment Outcome; D020246:Venous Thrombosis / Q000188:drug therapy* / Q000235:genetics*
D001779:Blood Coagulation Factors; D005343:Fibrinolytic Agents; D013300:Streptokinase